Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

Core Insights - Adaptive Biotechnologies Corporation announced the inclusion of its clonoSEQ® test for measurable residual disease (MRD) assessment in presentations at major oncology conferences, ASCO and EHA, highlighting its significance in blood cancer treatment [1][2] Company Overview - Adaptive Biotechnologies is a commercial-stage biotechnology company focused on translating the genetics of the adaptive immune system into clinical products for disease diagnosis and treatment [1][13] - The company leverages its proprietary immune medicine platform to develop diagnostics and therapeutics, particularly in the areas of MRD and immune medicine [13] Product Significance - The clonoSEQ test is recognized as the gold standard for MRD assessment, providing reliable insights for clinicians and aiding drug developers in advancing therapeutics [2] - MRD status is a critical predictor of outcomes in blood cancers, enabling personalized treatment monitoring and early relapse detection [2][12] Clinical Evidence - Data to be presented at ASCO and EHA will reinforce the clinical benefits of clonoSEQ, including: - A study showing strong correlation between bone marrow and peripheral blood MRD assessments in pediatric acute lymphoblastic leukemia (ALL), suggesting a less invasive monitoring method [3] - Evidence supporting the importance of sustained MRD negativity in multiple myeloma (MM) for predicting overall survival (OS) and progression-free survival (PFS) [3] - Findings from the MRD2STOP study indicating that clonoSEQ testing may help identify patients who can safely discontinue maintenance therapy while maintaining MRD negativity [3] Presentation Highlights - Key presentations at ASCO and EHA will cover various topics, including: - Efficacy and safety of CAR-T therapies in blood cancers [4][5] - Analysis of MRD in multiple myeloma treatment regimens [6][7] - Studies on chronic lymphocytic leukemia (CLL) and follicular lymphoma [8][10] Regulatory Status - clonoSEQ is the first and only FDA-cleared in vitro diagnostic test for detecting MRD in specific blood cancers, including multiple myeloma and B-cell acute lymphoblastic leukemia [11]